Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
19 June, 2018 06:45 IST
Dr. Reddy's Lab gets first-cycle approval for Impoyz cream
Source: IRIS | 01 Dec, 2017, 11.42AM
Comments  |  Post Comment

Dr. Reddy's Laboratories, through its wholly owned subsidiary Promius Pharma, LLC, has received fifth consecutive, first-cycle NDA approval for the Proprietary Products Group, a substantial milestone within the pharmaceutical industry.

Impoyz (clobetasol propionate) Cream, 0.025% is a high potency topical steroid approved for the treatment of moderate to severe plaque psoriasis in patients 18 years of age or older. The most common side effect of IMPOYZ Cream includes discoloration of the treated site. Psoriasis is a serious medical condition affecting approximately 7.5 million people in the United States. Impoyz, formerly referred to as DFD-06, had been recently licensed to Encore Dermatology Inc. for the commercialization of the product in the United States.

This approval is another example of the deep and broad capabilities within the Proprietary Products business unit at Dr. Reddy's. (Q,N,C,F)* The organization has achieved several milestones within drug, device, and formulation research and development for novel therapies.

Shares of the company declined Rs 11.35, or 0.5%, to trade at Rs 2,275.00. The total volume of shares traded was 12,848 at the BSE (11.27 a.m., Friday).

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Dr. Reddy's defends right to launch Buprenorphine and Naloxone Sublingual Film - 18-Jun-2018 12:40
Lupin, Nichi-Iko in pact for commercialisation of Etanercept in Japan - 18-Jun-2018 11:38
Yes Bank gets SEBI approval for offering custodial services - 18-Jun-2018 10:06
Fitch affirms at Axis Bank and ICICI Bank's issuer rating at BBB- - 15-Jun-2018 15:36
Fitch affirms at Axis Bank and ICICI Bank's issuer rating at BBB- - 15-Jun-2018 15:36
Dhunseri Petrochem to exit JV in Egypt with Indorama - 15-Jun-2018 15:22
NBCC bags orders worth Rs 4.80 bn in May 2018 - 15-Jun-2018 15:16
Jammu and Kashmir Bank to raise tier-I capital up to Rs 10 bn - 15-Jun-2018 11:26
Alembic Pharma receives EIR for formulation facility at Panelav - 15-Jun-2018 10:39
MERC reserves order on R-Infra's sale of Mumbai power biz to Adani - 15-Jun-2018 10:16
Dr. Reddy's receives nod for Buprenorphine, Naloxone Sublingual film - 15-Jun-2018 09:50
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer